News

Cerillo Introduces the Industry’s First Standardized Co-Culture System — Duet Revolutionizes Microbial Interaction and Isolation Studies

Cerillo, a leader in cellular analytics, announces the release of Duet, the first standardized co-culture system that allows researchers to explore microbial and cellular interactions in real time. Designed to address challenges in microbial research, Duet offers a novel approach to studying the dynamics between different microbial populations, enabling more precise, reproducible, and reliable results in fields ranging from synthetic biology to antimicrobial resistance.

The Duet Co-culture system is poised to be a game-changer for research in areas such as synthetic biology, antimicrobial resistance, fermentation, microbiome studies, women’s health and engineering complex microbial communities. By enabling fluidic interaction between distinct microbial populations while maintaining physical separation, Duet allows researchers to explore complex microbial communities and interactions—without the typical time and cost constraints.

“We developed Duet to address the need for a system that would allow researchers to systematically investigate microbial interactions,” said Eric Mayton, CEO of Cerillo. “By providing real-time phenotypic measurements, Duet enables deeper insights into these interactions, which are crucial for understanding everything from antimicrobial resistance to community-based behaviors.”

The Duet system has already demonstrated its impact in antimicrobial resistance research, an area where understanding mobile genetic elements and drivers of resistance can lead to critical breakthroughs. Alan J. Wolfe, Ph.D., Professor of Microbiology and Immunology at Loyola University in Chicago, highlighted how Duet has accelerated his lab’s research. “Using Duet, my postdoc was able to achieve results in two weeks that would have taken two months with traditional methods,” said Wolfe. “The system has allowed us to significantly improve the efficiency of our experiments, providing us with high-quality data in a fraction of the time.”

For researchers studying phage therapy, where understanding the interactions between bacteria and bacteriophages is essential, Duet has opened new possibilities. Bryan Hsu, a researcher at Virginia Tech, emphasized how the system has made it possible to study bacterial growth curves and phage interactions more effectively. “Previously, examining phage-bacteria interactions in complex microbial communities required laborious and costly methods such as sequencing,” said Hsu. “With Duet, we can now use straightforward absorbance measurements, significantly simplifying our workflow and allowing us to collect critical data much faster.”

The Duet platform’s flexibility extends beyond microbial interaction studies. David Liu, a researcher now at Queen’s University Medical School, shared how the system has streamlined his crystallization experiments. “Duet has cut our experiment time in half and eliminated sterilization issues we faced with older systems,” Liu explained. “Its high-throughput capabilities have also allowed us to explore the role of various bacterial genera in processes like struvite stone formation more comprehensively.”

In synthetic biology, where constructing complex microbial communities is often a trial-and-error process, Duet provides clarity by allowing researchers to better understand how individual organisms interact. Steve Techtmann, Professor of Biological Sciences at Michigan Technological University, noted how the platform simplifies his work. “Duet allows us to rapidly screen for microbial interactions without the extensive downstream analyses that are typically required,” said Techtmann. “We can now design more efficient experiments and accelerate the process of building synthetic communities for specific purposes.”

 

Read more here.

Recent News

05/14/2025

Civica to start Chesterfield lab construction this summer, eyes Petersburg plant expansion

Nearly three years after announcing plans to build a laboratory in Chesterfield to support its manufacturing operations in Petersburg, Civica Rx is readying plans to kick off the project’s construction. The Utah-based nonprofit drugmaker said it will break ground this summer on a 50,000-square-foot facility at 11731 Meadowville Lane, in the Meadowville Technology Park near Chester.

05/07/2025

Adial Pharmaceuticals raises $2.75M

Glen Allen biopharma company Adial Pharmaceuticals Inc. (NASDAQ: ADIL) has raised $2.75 million from an institutional investor. The company, which specializes in therapies for addiction and related disorders, said it will use the new funding for working capital and general corporate purposes. The name of the investor was not disclosed, but Adial said a “health

05/07/2025

Adovate Granted New U.S. Patent for Therapeutic Uses of A2B Receptor Antagonists

Adovate, LLC (“Adovate” or the “Company”), a biopharmaceutical company developing novel therapeutics targeting adenosine receptors involved in major diseases, today announced that Patent Number 12,269,828 B2 was issued by the United States Patent and Trademark Office. This newly issued patent covers therapeutic uses of the Company’s lead molecule ADO-5030 and thousands of other novel molecules